Could J&J Trip up the Merck and Schering-Plough Deal?
By Taskin Ahmed
Pharma Deals Review: Vol 2009 Issue 3 (Table of Contents)
Published: 13 Mar-2009
DOI: 10.3833/pdr.v2009.i3.1076 ISSN: 1756-7874
Section: Mergers & Acquisitions
Fulltext:
Abstract
The change of ownership clause in the contract between Johnson & Johnson (J&J) and Schering-Plough over the control of two key products, Remicade® and golimumab, could be a stumbling block in the merger between Merck and Schering-Plough...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS